Bse 400 MidSmallCap Index

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, Gland Pharma has informed that it enclosed copies of the newspaper advertisement pertaining to Audited Financial Results of the Company for the financial year ended March 31, 2026. The advertisements were published in English and Telugu newspapers.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that: CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, announced that the Central Drugs Standard Control Organization (CDSCO) has granted Marketing Authorisation under Form CT 23 for Bevqolva®, a bevacizumab biosimilar indicated for metastatic carcinoma of the colon or rectum. The authorisation permits manufacture at CuraTeQ’s facility in Hyderabad and marketing of Bevqolva® in 100 mg/4mL and 400 mg/16 mL vial presentations.

The above information is a part of company’s filings submitted to BSE.

Uno Minda has informed that the Nomination & Remuneration Committee of the Board of the Company at its meeting held on, on May 16, 2026, had approved the allotment of 34,990 equity shares of the face value of Rs. 2/- each, pursuant to the exercise of Options by the grantees under Uno Minda Employees Stock Option Scheme, 2019. The Company is in the process of applying for the listing of these shares with the stock exchanges i.e., NSE and BSE. The paid-up equity share capital of the Company stands increased from Rs. 1,15,48,43,632/- to Rs. 1,15,49,13,612/- In terms of Regulations l0(c) of the SEBI (Share Based Employee Benefits& Sweat Equity) Regulations, 2021 (‘SEBI Regulations’), the details of the share allotted as above are given in the Annexure-1 to this intimation. Further, this intimation is in terms of Regulation 30 of the SEBI (LODR) Regulations, 2015, however, the company has informed that the aforesaid allotment of shares is not material in nature to the Company. The aforesaid disclosures are also being made available on the website of the Company at www.unominda.com. The Meeting commenced at 09:30 am and concluded at 09:40 am.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 29(1)(d) of the SEBI Listing Regulations, Aditya Birla Capital has informed that a meeting of the board of directors of the company is scheduled on May 20, 2026, to consider the proposal of raising of funds by way of issuance of equity shares or other securities of the company through permissible modes including by way of qualified institutional placement, preferential allotment or any other methods or combination thereof as may be permitted under applicable laws, including the Companies Act, 2013 read with the rules notified thereunder and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, subject to such regulatory/ statutory and corporate approvals as may be required.

The above information is a part of company’s filings submitted to BSE.